<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311336</url>
  </required_header>
  <id_info>
    <org_study_id>VCC 1012</org_study_id>
    <nct_id>NCT01311336</nct_id>
  </id_info>
  <brief_title>Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain</brief_title>
  <official_title>Randomized Phase II Pilot Study of Loratadine for the Prevention of Pain Caused by the Granulocyte Colony Stimulating Factor Pegfilgrastim</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the incidence of pegfilgrastim-induced back and leg
      pain and to determine whether the antihistamine loratadine can prevent pegfilgrastim-induced
      back and leg pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pegfilgrastim is a myeloid growth factor that stimulates neutrophil precursors and can be
      used to decrease infection risk associated with neutropenia. However pegfilgrastim may induce
      back and leg pain in 20-50% of patients. No intervention has been consistently successful in
      treating or preventing this pain.

      The exact mechanism of pegfilgrastim-induced pain is unknown but may be related to
      histamine-mediated inflammation. Several case reports and anecdotal reports have suggested
      efficacy of antihistamines for this indication.

      This study will have two parts. In the first part (Observational Phase), patients receiving
      pegfilgrastim will be surveyed to document the incidence of significant pegfilgrastim-induced
      back and leg pain. In the second part (Treatment Phase), patients who previously experienced
      such pain will be randomized to receive a 7-day course of either the antihistamine loratadine
      or placebo to determine whether pegfilgrastim-induced back and leg pain can be prevented with
      this intervention.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of pegfilgrastim-induced back and leg pain by administration of the antihistamine loratadine</measure>
    <time_frame>one week after pegfilgrastim</time_frame>
    <description>Patients who experience significant pegfilgrastim-induced back and leg pain during the first cycle of pegfilgrastim therapy are randomized to receive loratadine or placebo during the second cycle of pegfilgrastim therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of adverse events when loratadine is given to prevent pegfilgrastim-induced back and leg pain</measure>
    <time_frame>one week after pegfilgrastim</time_frame>
    <description>Adverse events will be recorded for patients receiving loratadine or placebo to prevent pegfilgrastim-induced back and leg pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pegfilgrastim-induced back and leg pain</measure>
    <time_frame>One week after pegfilgrastim</time_frame>
    <description>Patients receiving pegfilgrastim for the first time will be surveyed to document the incidence of significant pegfilgrastim-induced back and leg pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Pegfilgrastim-induced Back and Leg Pain</condition>
  <arm_group>
    <arm_group_label>Loratadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loratadine 10 mg once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine</intervention_name>
    <description>loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim</description>
    <arm_group_label>Loratadine</arm_group_label>
    <other_name>Claritin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologic or cytologic evidence of malignancy

          -  scheduled to receive pegfilgrastim with two consecutive cycles of similar chemotherapy
             with at least a 14 day interval between cycles

          -  adequate renal function: estimated creatinine clearance &gt; 30 ml/min

          -  adequate hepatic function: AST, ALT, total bilirubin &lt;= 2.5 x ULN

          -  age &gt;= 18 years

          -  performance status 0-3

          -  able to read and understand English

          -  signed Informed Consent

        Exclusion Criteria:

          -  history of hypersensitivity or intolerance to antihistamines

          -  concurrent use of antihistamines other than study medications during or for 2 days
             prior to the study period except for a single dose of antihistamine as required for
             administration of chemotherapy or blood transfusion

          -  concomitant use of amiodarone

          -  previous use of pegfilgrastim or filgrastim
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M Grunberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven M Grunberg, MD</last_name>
    <phone>802-656-5457</phone>
    <email>steven.grunberg@uvm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen M Wilson, MEd</last_name>
    <phone>802-656-4101</phone>
    <email>karen.m.wilson@uvm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Care of Maine</name>
      <address>
        <city>Brewer</city>
        <state>Maine</state>
        <zip>04412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas H Openshaw, MD</last_name>
      <phone>207-973-7478</phone>
      <email>topenshaw@emh.org</email>
    </contact>
    <investigator>
      <last_name>Thomas H Openshaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Hertler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Center for Cancer Medicine</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Dugan, DO</last_name>
      <phone>207-885-7600</phone>
      <email>duganm@mccm.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Dugan, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tracey Weisberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Thomas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <state>Maine</state>
        <zip>03909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Eneman, MD</last_name>
      <phone>207-351-3777</phone>
      <email>jeneman@yorkhospital.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Eneman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CR Wood Cancer Center</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <zip>12801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aqeel Gillani, MD</last_name>
      <phone>518-926-6700</phone>
      <email>aqeelgillani@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Aqeel Gillani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mountainview Medical Center</name>
      <address>
        <city>Berlin</city>
        <state>Vermont</state>
        <zip>05602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Valentine, MD</last_name>
      <phone>802-225-5400</phone>
      <email>john.valentine@cvmc.org</email>
    </contact>
    <investigator>
      <last_name>John Valentine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Ospina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vermont Cancer Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven M Grunberg, MD</last_name>
      <phone>802-656-5457</phone>
      <email>steven.grunberg@uvm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen M Wilson, MEd</last_name>
      <phone>802-656-4101</phone>
      <email>karen.m.wilson@uvm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven M Grunberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Schwartz, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vermont Center for Cancer Medicine</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Sanders, MD</last_name>
      <phone>802-655-3400</phone>
      <email>Dennis.Sanders@vtmednet.org</email>
    </contact>
    <investigator>
      <last_name>Paul Unger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dennis Sanders, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Nunnink, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Steven Grunberg</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Pegfilgrastim</keyword>
  <keyword>Loratadine</keyword>
  <keyword>Myalgia/arthralgia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

